Skip to content

Speeding the time-to-clinic with Optimer®

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies.

Speeding project timelines can be vital to the development of any life science product. Whether this involves a faster time-to-market or time-to-clinic, gaining this advantage over competitors for a novel drug class or diagnostic is potentially significant, where every month of lead time may count. Our new whitepaper shows how selecting the appropriate affinity ligand within your project could be critical to speeding development timelines.

Optimer cuts up to 75% off antibody development timelines

New research benchmarked Optimer development against current industry-standard monoclonal antibody processes to examine the different timescales involved with affinity ligand development.

Employing Optimer can reduce timelines by as much as 75% through fewer and faster development steps. This advantage could cut valuable months from development timelines, allowing researchers and developers to reach critical milestones faster and offer a competitive advantage in entering clinical trials earlier.

Don’t let long timelines kill your development

Affinity ligands, such as antibodies and aptamers, are employed across the life sciences as therapeutics, drug delivery vehicles, affinity chromatography ligands, and assay and diagnostic reagents. Any commercial product that utilises affinity ligands in such ways may rely on competitive timelines for success.

Unexpected process steps and delays that arise at any point in the development process may hinder a project’s success and result in its failure. To prevent this, researchers and developers need to have insight into all potential affinity ligand development steps and timescales prior to the initiation of any project.

Speeding development saves lives

The development of new therapeutics and diagnostics offers new hope to patients of previously untreatable diseases. It can also improve treatment efficacy and tolerability over current medicines to improve patient compliance. The ability to speed the development pipeline for these new treatments is crucial for patients: one study showed that over a million patient life years were lost for every year in development between the discovery and approval of a new therapeutic for cancer patients.

Developing a new drug from initial concept to commercialisation typically takes 10-15 years and is associated with an average cost of $1.3 billion. Diagnostic development is significantly faster but still takes 18-24 months, with costs of $12-55 million. Considering the cost and risk associated with such development and the importance of new treatments and tests for patients, any opportunity to increase efficiencies or reduce the time to clinic, even by a few months, offers clear value.

The Optimer advantage speeds time to clinic

Optimer discovery and development typically take 10-12 weeks, but we can speed our processes to deliver in as little as four weeks by aligning processes for speed rather than capacity if you have urgent needs. Compared to antibody discovery, which takes between 16-40 weeks, Optimer offers much clearer and faster development times. For this initial development stage alone, there is the opportunity to cut up to 90% from your timelines by using Optimer over antibodies.

To find out more about how Optimer stacks up against antibody development times and research that is seeking to increase these timelines and efficiencies further, sign up below to receive the whitepaper direct to your inbox or get in touch to talk to one of our experts about how Optimer could progress your next project.

Download whitepaper


affinity ligandantibody developmentOptimer

Start your next project with Aptamer Group

Contact one of our experts today